Tigecycline (TIG) exhibits broad-spectrum activity against many Gram-positive and Gram-negative pathogens. However, clinical resistance has emerged recently and has been detected following treatment with TIG.
There are couple of publications reporting emergence of resistance to tigecycline.
Tigecycline is the first clinically available drug in a new class of antibiotics called the glycylcyclines,and is structurally similar to tetracyclines and it has been approved by FDA on a fast track basis.
Tigecycline (Tygacil) is FDA-approved to treat complicated skin and skin structure infections (cSSSI), complicated intra-abdominal infections (cIAI), and community-acquired bacterial pneumonia (CABP) and is not approved / not indicated for treatment of diabetic foot infection or for hospital-acquired or ventilator-associated pneumonia.
Patients and their caregivers should talk with their health care professionals if they have any questions or concerns about Tygacil , as there are reports of death after the use of Tygacil both for the approved and unapproved indication and resulted in boxed warning by FDA, boxed warning by FDA is the strongest warning given to the drug.
I am of the strong opinion that the clinicians should reserve the use of Tygacil Injection only if there is no alternative options available.
Suppose added few points to the discussion.
Controlled studies are required before its use esp. in respiratory infections
- Badges
- Science method